Research News
May 08, 2009
A vicious cycle in which damage to nerve cells (neurons) in the spinal cord results in the loss of an important mechanism to protect neurons, causing more neuron loss, has been identified as a
May 01, 2009
Items in this article report on: causes of ALS, protective factors, familial ALS, sexuality survey, new book about ALS care
Researchers probe protective strategies
The idea that ALS may result from
April 18, 2009
A new gene therapy approach to "silencing" disease-causing genetic information has been developed by researchers at Rutgers University in Piscataway, N.J., and Integrated DNA Technologies in
April 01, 2009
Recently published findings from two independent groups have suggested possible treatment pathways for the merosin-deficient and integrin-deficient forms of congenital muscular dystrophy (CMD).
April 01, 2009
Nearly 600 conferees gathered at the South Point Hotel in Las Vegas Jan. 26-28, 2009, for the MDA National Clinic Directors’ Conference, where a number of speakers presented research and care updates
April 01, 2009
This article contains items about: Duchenne muscular dystrophy and spinal muscular atrophy
Exon-skipping trial allowed dystrophin production in 10 boys with DMD
On Jan. 21, 2009, AVI BioPharma of
April 01, 2009
Story includes research items about: Charcot-Marie-Tooth disease, congenital muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy (EDMD), type 1 myotonic muscular
April 01, 2009
Items in this article report on research findings as of April 1, 2009, including: genetic causes of ALS, familial ALS, arimoclomol, SOD1 ALS, modafinil, Iplex, ceftriaxone, lithium, stem cell model
March 15, 2009
Study results reported in the March 2009 issue of Muscle & Nerve indicate that modafinil (marketed under the brand name Provigil) "may be a promising intervention for fatigue in ALS (
March 04, 2009
Nearly 600 conferees gathered in Las Vegas Jan. 25-28 for the 2009 MDA National Clinic Directors Conference, where a number of experts presented a broad range of topics covering neuromuscular
March 01, 2009
ALS TDI and Asklepios collaborating on gene therapy development
The MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., and Asklepios BioPharmaceutical in Chapel Hill, N.C
March 01, 2009
Investigators are looking for an ALS-specific “profile” in blood and spinal-fluid samples.
When investigators coordinated by James Connor at Pennsylvania State University College of Medicine in
March 01, 2009
Catherine Lomen-Hoerth says some abnormal behaviors in people with ALS may be reaction to the disease; others may be something more.
Jean-Pierre Julien says immunization strategies may prove
February 27, 2009
Two independent research teams, one based in the United States and Canada and the other in the United Kingdom and Australia, have identified mutations in a gene called FUS on chromosome 16 as a cause
February 20, 2009
The U.S. Food and Drug Administration (FDA) has said yes to a small safety trial of nervous-system stem cells in people with recently sustained injuries to the middle (thoracic) part of the spinal
February 20, 2009
Researchers at several institutions in the United States and Sweden have found that a mutation in the gene for superoxide dismutase 1 (SOD1), known to cause ALS (amyotrophic lateral sclerosis) in
February 01, 2009
ALS drug-discovery research is proceeding on many fronts at the ALS Therapy Development Institute (ALS TDI), an MDA-supported laboratory in Cambridge, Mass., whose mission is to rapidly develop
February 01, 2009
MDA has begun a new research initiative in 2009: MDA Venture Philanthropy (MVP). Designed to bridge a crucial funding gap in the drug development process, MVP will focus on the discovery and clinical
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/14-2_motor-neurons.jpg)
February 01, 2009
Some studies suggest that motor neurons, even when healthy, can be killed by toxic neighbors. If so, converting these “sharks” to “dolphins” might slow the pace of ALS.
Since the earliest
January 31, 2009
On Jan. 21, AVI BioPharma of Portland, Ore., announced its experimental compound AVI4658 for the treatment of Duchenne muscular dystrophy (DMD) yielded promising results in a phase 1 clinical trial
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/clinical%20trials%20network%20LeadArt.jpg)
January 02, 2009
Update (Jan. 23, 2013): As of eary 2013, MDA's DMD Clinical Research Network includes these five sites: University of California, Davis (UC Davis); Nemours Children's Hospital in Orlando, Fla.;
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/Roadblur%2C%20780x400.jpg)
January 02, 2009
Speeding the course of clinical trials for Duchenne muscular dystrophy (DMD) and ALS (amyotrophic lateral sclerosis) is one of the main goals of MDA’s new clinical trial network – and the work
January 01, 2009
This article contains items about: Pompe disease (acid maltase deficiency), Lambert-Eaton myasthenic syndrome, Duchenne and Becker muscular dystrophies, mitochondrial myopathy, myasthenia gravis and
January 01, 2009
Story includes research items about: centronuclear myopathy; Duchenne, limb-girdle, and Emery-Dreifuss muscular dystrophies; and spinal muscular atrophy.
Blood-vessel narrowing implicated in
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/Drug%20Development.jpg)
January 01, 2009
In the era of molecular biology, the drug development process has moved from a “let’s try it and see what happens” approach to a scientifically based process of discovery and application.
For many of
Pages
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc. All rights reserved.
